[1] 石炳毅, 袁铭. 中国肾移植受者免疫抑制治疗指南(2016 版)[J]. 器官移植, 2016, 7(5):327-331. doi:  10.3969/j.issn.1674-7445.2016.05.001
[2] RODRÍGUEZ FABA O, BOISSIER R, BUDDE K, et al. European association of urology guidelines on renal transplantation: update 2018[J]. Eur Urol Focus,2018,4(2):208-215. doi:  10.1016/j.euf.2018.07.014
[3] BENTATA Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxi-city[J]. Artif Organs,2020,44(2):140-152. doi:  10.1111/aor.13551
[4] SHRESTHA B M. Two decades of tacrolimus in renal transplant: basic science and clinical evidences[J]. Exp Clin Transplant,2017,15(1):1-9.
[5] VAN GELDER T, VAN SCHAIK R H, HESSELINK D A. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation[J]. Nat Rev Nephrol,2014,10(12):725-731. doi:  10.1038/nrneph.2014.172
[6] EVANS W E, MCLEOD H L. Pharmacogenomics: drug disposition, drug targets, and side effects[J]. N Engl J Med,2003,348(6):538-549. doi:  10.1056/NEJMra020526
[7] 田普训, 敖建华, 李宁, 等. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3):213-226. doi:  10.3969/j.issn.1674-7445.2019.03.001
[8] LIABEUF S, CHEDDANI L, MASSY Z. Uremic toxins and clinical outcomes: the impact of kidney transplantation[J]. Toxins (Basel). 2018, 10 (6): 229.
[9] ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients[J]. J Am Soc Nephrol,2003,14(7):1889-1896. doi:  10.1097/01.ASN.0000073901.94759.36
[10] HU Y F, HE J, CHEN G L, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J]. Clin Chim Acta,2005,353(1-2):187-192. doi:  10.1016/j.cccn.2004.11.005
[11] 赵富磊, 李骞, 张峻. 基因多态性对肾移植患者他克莫司药代动力学影响的研究现状[J]. 中国临床药理学杂志, 2017, 33(23):2489-2492.
[12] PRASAD N, JAISWAL A, BEHERA M R, et al. Melding pharmacogenomic effect of MDR1 and CYP3A5 gene polymorphism on tacrolimus dosing in renal transplant recipients in northern India[J]. Kidney Int Rep,2020,5(1):28-38. doi:  10.1016/j.ekir.2019.09.013
[13] FREDERICKS S, MORETON M, REBOUX S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements[J]. Transplantation,2006,82(5):705-708. doi:  10.1097/01.tp.0000234942.78716.c0
[14] LOH P T, LOU H X, ZHAO Y, et al. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients[J]. Transplant Proc,2008,40(5):1690-1695. doi:  10.1016/j.transproceed.2008.04.010
[15] GERVASINI G, GARCIA M, MACIAS R M, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation[J]. Transpl Int,2012,25(4):471-480. doi:  10.1111/j.1432-2277.2012.01446.x